Literature DB >> 12185287

Analysis of mouse polyomavirus mutants with lesions in the minor capsid proteins.

Petra Mannová1, David Liebl1, Nina Krauzewicz2, Anna Fejtová1, Jitka Štokrová3, Zdena Palková1, Beverly E Griffin2, Jitka Forstová1.   

Abstract

Polyomavirus mutants E, Q and H, expressing non-myristylated VP2, were generated by replacing the N-terminal glycine residue with glutamic acid, glutamine or histidine, respectively. Viruses mutated in either VP2 or VP3 translation initiation codons were also prepared. All mutated genomes, when transfected into murine host cells, gave rise to viral particles. Infectivity of VP2- and VP3- viruses, as measured by the number of cells expressing viral antigens, was dramatically diminished, indicative of defects in the early stages of infection. In contrast, the absence of a myristyl moiety on VP2 did not substantially affect the early steps of virus infection. No differences in numbers of cells expressing early or late viral antigens were observed between wild-type (wt) and E or Q myr- viruses during the course of a life cycle. Furthermore, no delay in virus DNA replication was detected. However, when cells were left for longer in culture, the number of infected cells, measured by typical virus bursts, was much lower when mutant rather than wt genomes were used. In situ, cell fractionation studies revealed differences in the interaction of viral particles with host cell structures. The infectivity of mutants was affected not only by loss of the myristyl group on VP2, but also, and to a greater extent, by alterations of the N-terminal amino acid composition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12185287     DOI: 10.1099/0022-1317-83-9-2309

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Chromosome-protein interactions in polyomavirus virions.

Authors:  Mariarosaria Carbone; Giuseppe Ascione; Silvia Chichiarelli; Marie-Isabelle Garcia; Margherita Eufemi; Paolo Amati
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

2.  Identification of amino acid residues within simian virus 40 capsid proteins Vp1, Vp2, and Vp3 that are required for their interaction and for viral infection.

Authors:  Akira Nakanishi; Akiko Nakamura; Robert Liddington; Harumi Kasamatsu
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  JC virus minor capsid proteins Vp2 and Vp3 are essential for virus propagation.

Authors:  M L Gasparovic; G V Gee; W J Atwood
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

4.  The Presumed Polyomavirus Viroporin VP4 of Simian Virus 40 or Human BK Polyomavirus Is Not Required for Viral Progeny Release.

Authors:  Stian Henriksen; Terkel Hansen; Jack-Ansgar Bruun; Christine Hanssen Rinaldo
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

5.  Minor capsid proteins of simian virus 40 are dispensable for nucleocapsid assembly and cell entry but are required for nuclear entry of the viral genome.

Authors:  Akira Nakanishi; Noriko Itoh; Peggy P Li; Hiroshi Handa; Robert C Liddington; Harumi Kasamatsu
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

6.  A chaperone-activated nonenveloped virus perforates the physiologically relevant endoplasmic reticulum membrane.

Authors:  Emily K Rainey-Barger; Brian Magnuson; Billy Tsai
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

7.  The Merkel cell polyomavirus minor capsid protein.

Authors:  Rachel M Schowalter; Christopher B Buck
Journal:  PLoS Pathog       Date:  2013-08-22       Impact factor: 6.823

8.  High cooperativity of the SV40 major capsid protein VP1 in virus assembly.

Authors:  Santanu Mukherjee; Mahmoud Abd-El-Latif; Michal Bronstein; Orly Ben-nun-Shaul; Stanislav Kler; Ariella Oppenheim
Journal:  PLoS One       Date:  2007-08-22       Impact factor: 3.240

Review 9.  Microtubules in Polyomavirus Infection.

Authors:  Lenka Horníková; Kateřina Bruštíková; Jitka Forstová
Journal:  Viruses       Date:  2020-01-18       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.